3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
10
Phase 1/2
3
Phase 1
3
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
44
Lung Neoplasms
13
Pancreatic Neoplasms
5
Non-Squamous Non-Small Cell Lung Cancer
5
Neoplasms
4
Colorectal Neoplasms
3
Thoracic Neoplasms
2
Respiratory Tract Diseases
2
Neoplasm Metastasis
2
Carcinoma
2
Brain Neoplasms
2
Stage IV EGFR Mutated Non-Small Cell Lung Cancer
1
Solid Tumor
1
Respiratory Tract Neoplasms
1
Rectal Neoplasms
1
Pancreatic Intraductal Neoplasms
1
Ovarian Neoplasms
1
Non-squamous Non-small Cell Lung Cancer
1
Non - Small Cell Lung Cancer NSCLC
1
Neoplasms by Site
1
NSCLC
1
Mouth Neoplasms
1
Lung Diseases
1
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
1
Head and Neck Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Ovarian Epithelial
1
Interventions
Sorafenib
42
lenvatinib
21
Fluorouracil
16
atezolizumab
15
Oxaliplatin
14
Bevacizumab
13
Doxorubicin
12
Radiosurgery
11
Leucovorin
11
Radiofrequency Ablation
10
Ethiodized Oil
10
pembrolizumab
7
Folfox protocol
7
sintilimab
6
durvalumab
6
Radiotherapy
6
Nivolumab
6
Epirubicin
6
Cisplatin
6
tremelimumab
5
Gemcitabine
5
apatinib
4
Embolization, Therapeutic
4
tislelizumab
3
camrelizumab
3
cabozantinib
3
Tenofovir
3
Pharmaceutical Preparations
3
Mitomycin
3
Magnetic Resonance Spectroscopy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Carcinoma, Hepatocellular
×
Erlotinib Hydrochloride
×
Clear all
NCT00901901
2019-05-30
SEARCH
Bayer
Phase 3
Completed
732 enrolled
18 charts